The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial).
 
Matthias Philip Ebert
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Nadja M Meindl-Beinker
Employment - IQVIA (I); Seqirus (I)
Stock and Other Ownership Interests - Bayer (I); BioNTech (I)
 
Tobias Gutting
No Relationships to Disclose
 
Martin Maenz
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Johannes Betge
No Relationships to Disclose
 
Nadine Schulte
No Relationships to Disclose
 
Tianzuo Zhan
Stock and Other Ownership Interests - Abbvie; Bayer; Merck; Novartis; Sanofi
 
Philip Weidner
No Relationships to Disclose
 
Ralf-Dieter Hofheinz
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
 
Arndt Vogel
Honoraria - Amgen; Bristol-Myers Squibb; Ipsen; Janssen; Lilly; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Bayer; BTG; Eisai; IPSEN; Lilly; Novartis; Pierre Fabre; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Stefan Angermeier
No Relationships to Disclose
 
Maike de Wit
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Ipsen; Jazz Pharmaceuticals
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Ipsen; Janssen; MSD; Nutricia; Sanofi
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genzyme (Inst); Ipsen (Inst); Janssen (Inst); MorphoSys (Inst); MSD (Inst); Noona Healthcare (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Pierre Fabre (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Pfizer; Takeda
 
Ralf Jakobs
Honoraria - Bristol-Myers Squibb; Falk Foundation
Research Funding - Bristol-Myers Squibb (Inst); OPIS (Inst)
 
Meinolf Karthaus
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen
 
Gertraud Stocker
Stock and Other Ownership Interests - BioNTech
Honoraria - SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Taiho Oncology (Inst)
Expert Testimony - SERVIER
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Pfizer; Roche
Research Funding - Merck Serono (Inst)
 
Tobias Leidig
No Relationships to Disclose
 
Nicolai Haertel
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene
Research Funding - Celgene (Inst)